PSID- Solutions to the Problem of Ebola Screening

Recommended Stock Newsletters
 
#1. PennyStockWarfare
#2. Nova Stocks
#3. Penny Stock Finder

SmallCapVoice Newsletter

Solutions to the Problem of Ebola Screening —————————————————————– Hot Stock to Watch —————————————————————– Company: PositiveID Corporation (OTCQB: PSID) Last:

Price: 0.063 Change (%): + 0.009 (16.67) Volume: 3,425,170 http://app.getresponse.com/click.htmlx=a62b&lc=QlSvT&mc=BT&s=V2HFR&u=BEqW&y=h& PositiveID Corporation: Able to Implement Safe, Accurate and Reliable Solutions to the Problem of Ebola Screening Ebola has dominated the news the past few months. Considering the recent outbreak in Africa has already killed thousands, and with no functional cure or treatment, it will continue to dominate the news for a while longer. The Ebola virus remains dormant in a host, allowing a victim to go symptom free for weeks making charting the path of the disease an extremely important one while also incredibly difficult. After the person starts having symptoms they get progressively worse before a majority of the sufferers die. What makes Ebola so scary is that, while it is currently contained to parts of Africa, it can spread to other parts of the world relatively easily. To make matters worse, the current ways we test for Ebola are slow, inefficient, and extremely expensive. Luckily there is a company such as PositiveID Corporation that can implement safe, accurate and reliable solutions to the problem of Ebola screening and help make sure this catastrophic disease doesn’t spread.

Currently, some airports in Africa have started screening passengers that arrive from countries that have experienced an Ebola outbreak. Unfortunately, the way they do this is less than effective. A passenger that is determined to have an elevated temperature and deemed feverish will then be subject to a blood test. This initial screening already creates problems. First, the way airport officials determine whether a passenger has a fever is with a very expensive thermal scanner. This thermal scanner is bulky and not a reliable method to detect someone that has an elevated body temperature. In fact, it is the same technology that failed to curb the spread of bird flu in 2009. Since temperature is only elevated after the incubation period of the Ebola virus, even if the machines were one hundred percent reliable, passengers that carry the Ebola virus would still get past undetected since the newly infected will not have a fever.

Not to mention that everyone will present or show the symptoms slightly differently. So while one person may have a high fever when infected another may have a much milder initial response.

This is just the first of many problems with the current detection methods. After a passenger is deemed to be feverish, the next part of the diagnostic process can start and this will create its own slew of problems.

If a passenger has been proven to have an elevated temperature they will then be subject to a polymerase chain reaction blood test or PCR. This test will detect Ebola Virus antibodies in a person that is carrying the disease. However, giving every passenger with an elevated body temperature a blood test is not only impractical but extremely expensive. Also the test itself needs to be conducted by highly trained medical professionals in a laboratory which will delay the readiness of the results. This can create a logistical nightmare as passengers would need to be quarantined as they await their test results. Also, the availability of the required laboratories can be scarce in Africa and other developing parts of the world. It is clear that in order to stop the spread of Ebola to other parts of Africa and the rest of the world, it is essential to develop and implement better screening and diagnostic practices at airports to prevent the dissemination of infected passengers. The current options are clearly not going to accomplish this huge task. Luckily, a widely respected bio threat diagnostic company seems to have a solution.

PositiveID Corporation is that company. PSID has recently partnered and signed a Space Act Agreement with NASA to explore its handheld Firefly Dx handheld diagnostic tools to use with various industries such as the healthcare field and even agricultural fields. PositiveID Corporation has also begun testing its devices in extreme environments for use in various Department of Defense purposes such as detection of biological terrorism. PSID also recently partnered with other contractors working with the Department of Defense and the U.S. Defense Threat Reduction Agency to develop their technology to detect Weapons of Mass destruction.

Continue Reading – http://app.getresponse.com/click.htmlx=a62b&lc=QlS20&mc=BT&s=V2HFR&u=BEqW&y=Y& —————————————————————– IMPORTANT DISCLAIMER – PLEASE READ THOROUGHLY —————————————————————– SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security.

SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com.

opt out of our distribution list at any time by clicking on the “

 
This entry was posted in SmallCapVoice and tagged . Bookmark the permalink.

Comments are closed.